Suchen
Enlivex Therapeutics Ltd
ENLVZur Watchlist hinzufügen
1.580USD
0.0000.00%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
25.00MMarktkapitalisierung
0.06KGV TTM
mehr Informationen über Enlivex Therapeutics Ltd Unternehmen
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Enlivex Therapeutics Ltd Profil
BörsenkürzelENLV
Name des UnternehmensEnlivex Therapeutics Ltd
IPO-datumJul 30, 2014
CEOHershkovitz (Oren)
Anzahl der mitarbeiter36
WertpapierartOrdinary Share
GeschäftsjahresendeJul 30
Addresse14 Einstein St.
StadtNESS-ZIONA
BörseNASDAQ OMX - NASDAQ BASIC
LandIsrael
Postleitzahl7403618
Telefon97286623301
Websitehttps://www.enlivex.com/
BörsenkürzelENLV
IPO-datumJul 30, 2014
CEOHershkovitz (Oren)
Führungskräfte von Enlivex Therapeutics Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Shai A. Novik
Mr. Shai A. Novik
Executive Chairman of the Board
Executive Chairman of the Board
464.93K
+87.69%
Mr. Shai A. Novik
Mr. Shai A. Novik
Executive Chairman of the Board
Executive Chairman of the Board
464.93K
+87.69%
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
12.22K
+1.05%
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
12.22K
+1.05%
Mrs. Shachar Shlosberger, CPA
Mrs. Shachar Shlosberger, CPA
Chief Financial Officer
Chief Financial Officer
2.01K
+78.69%
Mrs. Shachar Shlosberger, CPA
Mrs. Shachar Shlosberger, CPA
Chief Financial Officer
Chief Financial Officer
2.01K
+78.69%
Dr. Gili Hart, Ph.D.
Dr. Gili Hart, Ph.D.
Independent Director
Independent Director
481.00
+26.61%
Dr. Gili Hart, Ph.D.
Dr. Gili Hart, Ph.D.
Independent Director
Independent Director
481.00
+26.61%
Mr. Sangwoo Lee
Mr. Sangwoo Lee
Director
Director
--
--
Dr. Bernhard Jurgen Kirschbaum, Ph.D.
Dr. Bernhard Jurgen Kirschbaum, Ph.D.
Director
Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Shai A. Novik
Mr. Shai A. Novik
Executive Chairman of the Board
Executive Chairman of the Board
464.93K
+87.69%
Mr. Shai A. Novik
Mr. Shai A. Novik
Executive Chairman of the Board
Executive Chairman of the Board
464.93K
+87.69%
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
12.22K
+1.05%
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
12.22K
+1.05%
Mrs. Shachar Shlosberger, CPA
Mrs. Shachar Shlosberger, CPA
Chief Financial Officer
Chief Financial Officer
2.01K
+78.69%
Mrs. Shachar Shlosberger, CPA
Mrs. Shachar Shlosberger, CPA
Chief Financial Officer
Chief Financial Officer
2.01K
+78.69%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Enlivex Therapeutics Ltd?
Die fünf größten Anteilseigner von Enlivex Therapeutics Ltd sind: Mr. Shai A. Novik
Wie viele Institutionen halten Anteile an Enlivex Therapeutics Ltd (ENLV)?
Mit Stand vom 2026Q1 halten 44 Institutionen Anteile an Enlivex Therapeutics Ltd, mit einem Gesamtmarktwert von etwa 2.13M, was 0.89% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -1519291.00 gestiegen.